STAGE IV UVEAL MELANOMA AJCC V7
Clinical trials for STAGE IV UVEAL MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV UVEAL MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV UVEAL MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for rare eye cancer
Disease control OngoingThis study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could slow cancer growth better than trametinib alone. Participants received either one or …
Matched conditions: STAGE IV UVEAL MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New hope for rare eye cancer: drug targets tumor growth
Disease control OngoingThis study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. Vorinostat works by blocking certain enzymes that cancer cells need to grow. The main goal is to see how many patients' tumors shrink or disappear, and researche…
Matched conditions: STAGE IV UVEAL MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:58 UTC